GlaxoSmithKline (GB:GSK) has released an update.
GlaxoSmithKline has announced the Japanese regulatory acceptance for review of Blenrep in combination with BorDex or PomDex for relapsed or refractory multiple myeloma, a decision supported by positive phase III trial results. With over 7,200 new cases of multiple myeloma diagnosed in Japan annually, these Blenrep combinations, if approved, could significantly impact the treatment landscape for this challenging condition. The drug’s efficacy in improving progression-free survival has been demonstrated in the DREAMM-7 and DREAMM-8 trials, offering hope for more effective treatment options.
For further insights into GB:GSK stock, check out TipRanks’ Stock Analysis page.
